You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Eli
since
auto-detected in 106 stories
4 days ago
Lilly shares rose more than 4% Monday, while rival Novo Nordisk tanked.
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen ⊕
Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.
9 days ago
Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study ⊕
Eli Lilly said on Wednesday the combined use of its weight-loss drug Zepbound with psoriasis treatment Taltz showed better results in a late-stage study.
22 days ago
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026 ⊕⊕
The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its direct-to-consumer sales strategy.
23 days ago
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar ⊕
Eli Lilly's fourth-quarter earnings come as it tries to maintain its advantage over Novo Nordisk in the GLP-1 market.
27 days ago
Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch ⊕
Lilly CEO Dave Ricks is confident in the ability of the company's pill to compete and is preparing for a "full launch" in the second quarter.
Eli Lilly looks to sharpen its domestic supply edge by building another U.S. plant ○
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
28 days ago
Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections ○
The plant will help make Lilly's experimental drug called retatrutide, which has shown the highest weight loss seen to date in a late-stage trial.
66 days ago
Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale ⊕
Club holding Lilly stock slumped 1% Tuesday while Novo Nordisk shares jumped nearly 9%.
71 days ago
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound ⊕
found
Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for obesity.